Assyro AI

Orange Book product · Brand (NDA)

KISQALI

RIBOCICLIB SUCCINATE

Brand (NDA)NDA 209092RX NOVARTIS

At a glance

Mar 13, 2017

Approved

Brand (NDA)

Application

Not listed

TE code

43

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Mar 13, 2017

    9 yr 5 mo ago

  2. Today

  3. Exclusivity ends · I-950

    New indication exclusivity (3 years)

    Sep 17, 2027

    in 1 yr 3 mo

  4. Exclusivity ends · PED

    Pediatric exclusivity (adds 6 months)

    Mar 17, 2028

    in 1 yr 9 mo

  5. Patent 8324225 expires

    Listed drug substance patent expiration.

    Jun 17, 2028

    in 2 yr

  6. Patent 8324225*PED expires

    Listed listed patent expiration.

    Dec 17, 2028

    in 2 yr 6 mo

  7. Patent 9416136 expires

    Listed method-of-use patent (U-2355) expiration.

    Aug 20, 2029

    in 3 yr 3 mo

  8. Patent 9416136 expires

    Listed method-of-use patent (U-2356) expiration.

    Aug 20, 2029

    in 3 yr 3 mo

  9. Patent 9416136 expires

    Listed method-of-use patent (U-1981) expiration.

    Aug 20, 2029

    in 3 yr 3 mo

  10. Patent 9416136 expires

    Listed method-of-use patent (U-3999) expiration.

    Aug 20, 2029

    in 3 yr 3 mo

  11. Patent 9416136 expires

    Listed method-of-use patent (U-3266) expiration.

    Aug 20, 2029

    in 3 yr 3 mo

  12. Patent 9416136 expires

    Listed method-of-use patent (U-3265) expiration.

    Aug 20, 2029

    in 3 yr 3 mo

  13. Patent 9416136 expires

    Listed method-of-use patent (U-3975) expiration.

    Aug 20, 2029

    in 3 yr 3 mo

  14. Patent 8962630 expires

    Listed method-of-use patent (U-1981) expiration.

    Dec 09, 2029

    in 3 yr 6 mo

  15. Patent 8962630 expires

    Listed method-of-use patent (U-2356) expiration.

    Dec 09, 2029

    in 3 yr 6 mo

  16. Patent 8962630 expires

    Listed method-of-use patent (U-2355) expiration.

    Dec 09, 2029

    in 3 yr 6 mo

  17. Patent 8962630 expires

    Listed method-of-use patent (U-3999) expiration.

    Dec 09, 2029

    in 3 yr 6 mo

  18. Patent 8962630 expires

    Listed method-of-use patent (U-3265) expiration.

    Dec 09, 2029

    in 3 yr 6 mo

  19. Patent 8962630 expires

    Listed method-of-use patent (U-3266) expiration.

    Dec 09, 2029

    in 3 yr 6 mo

  20. Patent 8962630 expires

    Listed method-of-use patent (U-3975) expiration.

    Dec 09, 2029

    in 3 yr 6 mo

  21. Patent 9416136*PED expires

    Listed listed patent expiration.

    Feb 20, 2030

    in 3 yr 9 mo

  22. Patent 8685980 expires

    Listed drug substance patent expiration.

    May 25, 2030

    in 4 yr

  23. Patent 8962630*PED expires

    Listed listed patent expiration.

    Jun 09, 2030

    in 4 yr

  24. Patent 8685980*PED expires

    Listed listed patent expiration.

    Nov 25, 2030

    in 4 yr 6 mo

  25. Patent 8415355 expires

    Listed drug substance patent expiration.

    Mar 13, 2031

    in 4 yr 10 mo

  26. Patent 8415355*PED expires

    Listed listed patent expiration.

    Sep 13, 2031

    in 5 yr 4 mo

  27. Patent 9193732 expires

    Listed drug substance patent expiration.

    Nov 09, 2031

    in 5 yr 6 mo

  28. Patent 9868739 expires

    Listed method-of-use patent (U-2355) expiration.

    Nov 09, 2031

    in 5 yr 6 mo

  29. Patent 9868739 expires

    Listed method-of-use patent (U-2356) expiration.

    Nov 09, 2031

    in 5 yr 6 mo

  30. Patent 9868739 expires

    Listed method-of-use patent (U-3999) expiration.

    Nov 09, 2031

    in 5 yr 6 mo

  31. Patent 9868739 expires

    Listed method-of-use patent (U-1981) expiration.

    Nov 09, 2031

    in 5 yr 6 mo

  32. Patent 9868739 expires

    Listed method-of-use patent (U-3975) expiration.

    Nov 09, 2031

    in 5 yr 6 mo

  33. Patent 9868739 expires

    Listed method-of-use patent (U-3265) expiration.

    Nov 09, 2031

    in 5 yr 6 mo

  34. Patent 9868739 expires

    Listed method-of-use patent (U-3266) expiration.

    Nov 09, 2031

    in 5 yr 6 mo

  35. Patent 9193732*PED expires

    Listed listed patent expiration.

    May 09, 2032

    in 6 yr

  36. Patent 9868739*PED expires

    Listed listed patent expiration.

    May 09, 2032

    in 6 yr

  37. Patent 12544379 expires

    Listed method-of-use patent (U-3975) expiration.

    Aug 07, 2034

    in 8 yr 3 mo

  38. Patent 12544380 expires

    Listed method-of-use patent (U-4404) expiration.

    Aug 07, 2034

    in 8 yr 3 mo

  39. Patent 12544380 expires

    Listed method-of-use patent (U-4405) expiration.

    Aug 07, 2034

    in 8 yr 3 mo

  40. Patent 12544379*PED expires

    Listed listed patent expiration.

    Feb 07, 2035

    in 8 yr 9 mo

  41. Patent 12544380*PED expires

    Listed listed patent expiration.

    Feb 07, 2035

    in 8 yr 9 mo

  42. Patent 10799506 expires

    Listed drug product patent expiration.

    Apr 14, 2036

    in 10 yr

  43. Patent 12064434 expires

    Listed drug product patent expiration.

    Apr 14, 2036

    in 10 yr

  44. Patent 12419894 expires

    Listed drug product patent expiration.

    Apr 14, 2036

    in 10 yr

  45. Patent 10799506*PED expires

    Listed listed patent expiration.

    Oct 14, 2036

    in 10 yr 6 mo

  46. Patent 12064434*PED expires

    Listed listed patent expiration.

    Oct 14, 2036

    in 10 yr 6 mo

  47. Patent 12419894*PED expires

    Listed listed patent expiration.

    Oct 14, 2036

    in 10 yr 6 mo

Pharmaceutical detail

Active ingredient

RIBOCICLIB SUCCINATE

Strength

EQ 200MG BASE

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 209092

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

  • I-950New indication exclusivity (3 years)

    Sep 17, 2027

    in 1 yr 3 mo

  • PEDPediatric exclusivity (adds 6 months)

    Mar 17, 2028

    in 1 yr 9 mo

Listed patents (43)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8324225Jun 17, 2028in 2 yr
SubstanceProduct
8324225*PEDDec 17, 2028in 2 yr 6 mo
9416136Aug 20, 2029in 3 yr 3 mo
U-2355
9416136Aug 20, 2029in 3 yr 3 mo
U-2356
9416136Aug 20, 2029in 3 yr 3 mo
U-1981
9416136Aug 20, 2029in 3 yr 3 mo
U-3999
9416136Aug 20, 2029in 3 yr 3 mo
U-3266
9416136Aug 20, 2029in 3 yr 3 mo
U-3265
9416136Aug 20, 2029in 3 yr 3 mo
U-3975
8962630Dec 09, 2029in 3 yr 6 mo
U-1981
8962630Dec 09, 2029in 3 yr 6 mo
U-2356
8962630Dec 09, 2029in 3 yr 6 mo
U-2355
8962630Dec 09, 2029in 3 yr 6 mo
U-3999
8962630Dec 09, 2029in 3 yr 6 mo
U-3265
8962630Dec 09, 2029in 3 yr 6 mo
U-3266
8962630Dec 09, 2029in 3 yr 6 mo
U-3975
9416136*PEDFeb 20, 2030in 3 yr 9 mo
8685980May 25, 2030in 4 yr
SubstanceProduct
8962630*PEDJun 09, 2030in 4 yr
8685980*PEDNov 25, 2030in 4 yr 6 mo
8415355Mar 13, 2031in 4 yr 10 mo
SubstanceProduct
8415355*PEDSep 13, 2031in 5 yr 4 mo
9193732Nov 09, 2031in 5 yr 6 mo
SubstanceProduct
9868739Nov 09, 2031in 5 yr 6 mo
U-2355
9868739Nov 09, 2031in 5 yr 6 mo
U-2356
9868739Nov 09, 2031in 5 yr 6 mo
U-3999
9868739Nov 09, 2031in 5 yr 6 mo
U-1981
9868739Nov 09, 2031in 5 yr 6 mo
U-3975
9868739Nov 09, 2031in 5 yr 6 mo
U-3265
9868739Nov 09, 2031in 5 yr 6 mo
U-3266
9193732*PEDMay 09, 2032in 6 yr
9868739*PEDMay 09, 2032in 6 yr
12544379Aug 07, 2034in 8 yr 3 mo
U-3975
12544380Aug 07, 2034in 8 yr 3 mo
U-4404
12544380Aug 07, 2034in 8 yr 3 mo
U-4405
12544379*PEDFeb 07, 2035in 8 yr 9 mo
12544380*PEDFeb 07, 2035in 8 yr 9 mo
10799506Apr 14, 2036in 10 yr
Product
12064434Apr 14, 2036in 10 yr
Product
12419894Apr 14, 2036in 10 yr
Product
10799506*PEDOct 14, 2036in 10 yr 6 mo
12064434*PEDOct 14, 2036in 10 yr 6 mo
12419894*PEDOct 14, 2036in 10 yr 6 mo
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.